Collagen Turnover Biomarkers Associate with Active Psoriatic Arthritis and Decrease with Guselkumab Treatment in a Phase 3 Clinical Trial (DISCOVER-2)

INTRODUCTION: Guselkumab, a novel interleukin-23p19 subunit monoclonal antibody, has been shown to effectively improve the diverse manifestations of active psoriatic arthritis (PsA) in two phase 3 trials (DISCOVER-1, DISCOVER-2). Serum concentrations of extracellular matrix (ECM) biomarkers at basel...

Descripción completa

Detalles Bibliográficos
Autores principales: Schett, Georg, Loza, Matthew J., Palanichamy, Arumugam, FitzGerald, Oliver, Ritchlin, Christopher, Bay-Jensen, Anne-Christine, Nielsen, Signe Holm, Gao, Sheng, Hsia, Elizabeth C., Kollmeier, Alexa P., Xu, Xie L., Baribaud, Frédéric, Sweet, Kristen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9314487/
https://www.ncbi.nlm.nih.gov/pubmed/35352313
http://dx.doi.org/10.1007/s40744-022-00444-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9314487/
https://www.ncbi.nlm.nih.gov/pubmed/35352313
http://dx.doi.org/10.1007/s40744-022-00444-x

Ejemplares similares